Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Jul 28, 2026 (2 months ago)

Libtayo (cemiplimab-rwlc)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01

Affected NDC 61755-0008-01

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Libtayo
cemiplimab-rwlc
NDC 61755-0008
CEMIPLIMAB 50 mg/mL Injection
Intravenous
Regeneron Pharmaceuticals, Inc. Rx
Recalling firm
Regeneron Pharmaceuticals Inc
NDC code
61755-008-01
Origin
NY, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0767-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Regeneron Pharmaceuticals Inc

All 2026 recalls
Class II · Moderate risk

Eylea

Lack of Assurance of Sterility: Complaints of syringe breakage

Terminated Sterility / contamination Regeneron Pharmaceuticals Inc NDC 61755-005-01 D-0531-2024
Class II · Moderate risk

Eylea

Lack of Assurance of Sterility: Complaints of syringe breakage

Terminated Sterility / contamination Regeneron Pharmaceuticals Inc NDC 61755-005-01 D-0479-2024

Other sterility / contamination recalls from 2026

All sterility / contamination recalls